Jeff Landau
Equibles does not estimate personal net worth.
About Jeff Landau
CytomX Therapeutics, Inc. reported in an 8-K filed February 3, 2025 that Jeff Landau was terminated as Senior Vice President, Chief Business Officer, and Head of Strategy, effective February 7, 2025. The proxy statement of CytomX Therapeutics, Inc. reports total compensation of $1,047,812 for Jeff Landau in fiscal 2023, including a base salary of $415,692. Disclosed compensation is on record for 3 fiscal years.
“On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the "Company") and the Company agreed that Mr. Landau's employment by the Company would terminate, effective February 7, 2025.”
Affiliation history
-
CytomX Therapeutics, Inc. (CTMX)
Proxy statement
Start not stated–2025-02-07
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Business Officer | $415,692 | $1,047,812 |
| 2022 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Business Officer | $393,333 | $1,060,903 |
| 2021 | CytomX Therapeutics, Inc. (CTMX) | Senior Vice President and Chief Business Officer | $274,924 | $1,755,321 |